Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2019-03-21 Board/Management Inform…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Scientific Advisory Board Appointment 3 pages 70.6KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement about the appointment of Dr. Rakesh Veedu to the Scientific Advisory Board of Phylogica. It contains no financial data, no mention of financial results, no regulatory filings, no voting results, no capital changes, and no legal proceedings. The content is focused on management/board-related information, specifically the appointment of a scientific advisory board member. The document length is 3890 characters, which is relatively short and consistent with an announcement rather than a detailed report. Therefore, the most appropriate classification is Board/Management Information (MANG).
2019-03-21 English
Collaboration Agreement - siRNA delivery 3 pages 78.2KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 14 March 2019 about a collaboration agreement between Phylogica and Tel Aviv University regarding siRNA delivery research. It discusses the details of the collaboration, the scientific background, and strategic focus. There are no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no mention of report attachments or certifications. The document is a corporate announcement about a research collaboration, which fits best under the category of Capital/Financing Update (CAP) as it relates to strategic partnership and R&D collaboration that could impact company value. It is not a report or regulatory filing, nor a presentation or earnings release. Therefore, the most appropriate classification is CAP with high confidence.
2019-03-13 English
Flagship Program - Successful Animal Models 4 pages 93.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Phylogica Ltd dated 12 March 2019. It discusses successful results from animal model studies related to their Cell Penetrating Peptides (CPPs) delivering drug cargoes. The content focuses on scientific and technical results, implications for future research, and next steps towards clinical development. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a detailed update on research progress and scientific findings rather than a financial report or regulatory filing. It is not a full annual or interim report, nor an earnings release or investor presentation. The document is a corporate announcement providing substantive information about the company's R&D progress and future plans, fitting best into the category of a general regulatory announcement or compliance update. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (7447 characters) and detailed content support this classification with high confidence.
2019-03-11 English
Half Yearly Report and Accounts 18 pages 649.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half-Year Report Period ended 31 December 2018' and contains detailed financial statements including a condensed statement of comprehensive income, statement of financial position, cash flows, and changes in equity for the half year ended 31 December 2018. It includes a directors' report, auditor's independence declaration, and notes to the financial statements. The content is comprehensive and covers actual financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. H1 2019
2019-02-27 English
Director Resignation and App3Z 4 pages 175.3KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 11 February 2019 regarding the resignation of a Non-Executive Director, Sahm Nasseri, from the Board of Directors of Phylogica Limited. It includes a statement from the CEO about the resignation and an Appendix 3Z Final Director’s Interest Notice, which is a regulatory form related to director interests and cessation of directorship. The content focuses on management changes and director interests, with no financial statements or detailed financial data. Therefore, it fits the category of Board/Management Information (MANG). The document length is about 5092 characters, sufficient to contain the full announcement and related director interest notice, not just a brief notice or link to a report. Hence, the classification is MANG with high confidence.
2019-02-10 English
First Competitive Read Out - Peptide Vaccine 3 pages 101.6KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 8 February 2019 from Phylogica Limited. It discusses the results of an in vivo competitive read-out of their Cell Penetrating Peptides (CPPs) technology in a peptide vaccine program, highlighting scientific and commercial implications. The content is focused on reporting experimental results and competitive advantages of their technology, not on financial results, management changes, or regulatory filings. The document is relatively short (5540 characters) and is an announcement of scientific progress and competitive evaluation rather than a detailed financial or management report. It does not contain financial statements or detailed financial data, nor is it a transcript, proxy, or legal proceeding. Therefore, it fits best into the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories such as Earnings Release or Investor Presentation.
2019-02-07 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.